

Biologics Market Competition Analysis 2025: How Players Are Shaping Growth

The Business Research Company's Biologics Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, December 9, 2025 /EINPresswire.com/ -- The Biologics market is dominated by a mix of global pharmaceutical leaders and specialized biotechnology innovators. Companies are focusing on advanced biomanufacturing technologies, next-



generation monoclonal antibodies, and cell and gene therapy platforms to strengthen their market position and expand therapeutic portfolios. Understanding the competitive landscape is key for stakeholders seeking to leverage innovation, optimize commercialization strategies, and

capture emerging growth opportunities within this rapidly evolving market.



The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights -Market Sizing & Forecasts Through 2034"

The Business Research
Company


Which Market Player Is Leading the Biologics Market? According to our research, Pfizer Inc. led global sales in 2024 with a 14% market share. The Biopharma division of the company is completely involved in the biologics market, provides a comprehensive biologics portfolio through its biopharma segment, encompassing monoclonal antibodies, vaccines, antibody-drug conjugates, and recombinant proteins. its contract

development and manufacturing organization, pfizer centreone, delivers end-to-end services including cell culture, microbial fermentation, antibody-drug conjugate assembly, viral vector and vaccine production, aseptic fill-finish in vials and prefilled syringes, and global regulatory support.

How Concentrated Is the Biologics Market?

The market is concentrated, with the top 10 players accounting for 65% of total market revenue

in 2024. This level of concentration underscores the capital-intensive nature of biologics development, characterized by advanced R&D capabilities, stringent regulatory requirements, and the need for largescale biomanufacturing and distribution infrastructure. Leading pharmaceutical companies such as Pfizer Inc., Merck & Co., Inc., F. Hoffmann-La Roche AG, and Johnson & Johnson dominate the market through extensive biologics portfolios, strong global presence, and consistent innovation in monoclonal antibodies and recombinant protein therapies. Other key players, including Regeneron Pharmaceuticals Inc., AbbVie Inc., Sanofi S.A., Amgen Inc., AstraZeneca plc, and Bristol Myers Squibb Company, strengthen their competitive positions through strategic alliances, biosimilar expansion, and targeted therapeutic advancements. As demand for personalized and high-efficacy



biologic treatments continues to grow, consolidation and collaboration among major players are expected to further reinforce the dominance of established biopharmaceutical leaders.

- Leading companies include:
- o Pfizer Inc. (14%)
- o Merck & Co. Inc. (9%)
- o F. Hoffmann-La Roche AG (9%)
- o Johnson & Johnson (7%)
- o Regeneron Pharmaceutical Inc. (6%)
- o AbbVie Inc. (5%)
- o Sanofi S.A. (4%)
- o Amgen Inc. (4%)
- o AstraZeneca plc (4%)
- o Bristol Myers Squibb Company (4%)

Request a free sample of the Biologics Market report:

https://www.thebusinessresearchcompany.com/sample_request?id=3606&type=smp

Which Companies Are Leading Across Different Regions?

- North America: Wacker Chemie AG, Forge Biologics Holdings LLC, LOTTE BIOLOGICS, Pinnacle Biologics, Inc., Alvotech, Ultragenyx Pharmaceutical Inc., Celltrion, Inc., Biocon Biologics Limited, Eurofins CDMO Alphora Inc., Formycon AG, Fresenius Kabi Aktiengesellschaft, Viatris Inc., WuXi Biologics (Cayman) Inc., and Abzena Limited are some of the leading companies in this region.
- Asia Pacific: Joinn Biologics, Inc., WuXi Biologics (Cayman) Inc., Sinovac Biotech Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Biocon Limited, Indian Immunologicals Limited (IIL), Dr. Reddy's Laboratories Ltd., Serum Institute of India Pvt. Ltd., Zydus Lifesciences Limited (formerly Zydus Cadila), Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Chugai Pharmaceutical Co., Ltd. (a subsidiary of F. Hoffmann-La Roche AG), Samsung Biologics Co., Ltd., Xbrane Biopharma AB, STADA Arzneimittel AG, Celltrion, Inc., LG Chem Life Sciences Division, CSL Limited, Patheon, Inc. (a Thermo Fisher Scientific company), Lonza Biologics AG, and Tessa Therapeutics Ltd are some of the leading companies in this region.
- Western Europe: EnteroBiotix Limited, Lonza Group AG, Sartorius AG, Bio-Rad Laboratories, Inc., Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, Cytena GmbH, Merck KGaA, GE HealthCare Technologies Inc., SGS S.A., Aenitis Technologies SAS, Bracco S.p.A., Gilead Sciences, Inc., ReNeuron Group plc, Sanofi S.A., Siemens Healthineers AG, Cytiva Europe GmbH, bioMérieux S.A., ImmerscioBio GmbH, Ciloa SAS, Differential Bio Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company (Lilly EU), Teva UK Limited, AstraZeneca plc, Abbott Laboratories, Vectura Group Limited, Procos S.p.A., BSP Pharmaceuticals S.p.A., 4Moving Biotech SAS, Coriolis Pharma Forschungs GmbH, Chiesi Farmaceutici S.p.A., and EXO Biologics S.A. are some of the leading companies in this region.
- Eastern Europe: Chime Biologics Limited, Polpharma Biologics S.A., Bioton S.A., Mabion S.A., Richter Gedeon Nyrt. (Biopharma Division), Egis Pharmaceuticals PLC, SOTIO Biotech AG (a subsidiary of PPF Group), Zentiva N.V., and Biopolis s.r.o. (now part of SOTIO Group) are some of the leading companies in this region.
- South America: Biotimize Soluções em Engenharia Ltda., Richmond Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Bionovis S.A. Companhia Brasileira de Biotecnologia Farmacêutica, and Artixio Lifesciences Private Limited are some of the leading companies in this region.

What Are the Major Competitive Trends in the Market?

- High-Concentration Biologic Formulations are drug delivery systems designed to contain higher doses of biologic agents in smaller volumes.
- Example: Samsung Biologics S-HiCon (October 2024) designed to optimize formulation stability and reduce viscosity.
- These innovations assists in early-stage feasibility screening through a proprietary Concentration Gate Check process, which helps identify optimal candidates and minimize formulation risks.

Which Strategies Are Companies Adopting to Stay Ahead?

• Expanding biomanufacturing capacity and global production networks

- Investing in research and development and advanced technologies
- Forming strategic partnerships and licensing agreements
- Enhancing regulatory compliance and quality assurance frameworks

Access the detailed Biologics Market report here:

https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Learn More About The Business Research Company

The Business Research Company (<u>www.thebusinessresearchcompany.com</u>) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company Americas +1 310-496-7795 Europe +44 7882 955267 Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook

This press release can be viewed online at: https://www.einpresswire.com/article/873510261

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.